Hanmi Pharmaceutical Co., Ltd. Sample Contracts
SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENTInvestor’s Rights Agreement • March 20th, 2025 • Hanmi Pharmaceutical Co., Ltd. • Biological products, (no disgnostic substances) • New York
This SECOND AMENDED AND RESTATED INVESTOR’S RIGHTS AGREEMENT (this “Agreement”), is made as of March 18, 2025, by and between Aptose Biosciences Inc., a Canadian corporation (the “Company”), and Hanmi Pharmaceutical Co., Ltd., a corporation incorporated under the laws of the Republic of Korea (the “Investor”).
DEBT CONVERSION AND INTEREST PAYMENT AGREEMENTDebt Conversion and Interest Payment Agreement • March 20th, 2025 • Hanmi Pharmaceutical Co., Ltd. • Biological products, (no disgnostic substances) • New York
This Debt Conversion and Interest Payment Agreement (this “Agreement”), dated March 18, 2025 (the “Effective Date”), is entered into by and between Aptose Biosciences Inc., a corporation incorporated pursuant to the Canada Business Corporations Act (the “Company”), and Hanmi Pharmaceutical Co., Ltd. (the “Lender”), a corporation incorporated under the laws of the Republic of Korea. The Company and the Lender are sometimes referred to herein individually as a “Party” and together as the “Parties.”
APTOSE BioSCIENCES INC. AMENDED AND RESTATED WARRANT TO PURCHASE COMMON SHARESSecurities Agreement • April 26th, 2024 • Hanmi Pharmaceutical Co., Ltd. • Biological products, (no disgnostic substances)
THIS COMMON SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, Hanmi Pharmaceutical Co., Ltd. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 31, 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Aptose Biosciences Inc., a company organized under the Canada Business Corporations Act (the “Corporation”), up to 2,339,181 common shares in the capital of the Corporation (“Common Shares” and, as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).